![Andrew J. Staples](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew J. Staples
Direktor/Vorstandsmitglied bei Entasis Therapeutics, Inc.
Aktive Positionen von Andrew J. Staples
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Entasis Therapeutics, Inc.
![]() Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Direktor/Vorstandsmitglied | 01.05.2015 | - |
Independent Dir/Board Member | 01.05.2015 | - |
Karriereverlauf von Andrew J. Staples
Ehemalige bekannte Positionen von Andrew J. Staples
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Direktor/Vorstandsmitglied | 01.05.2015 | 19.06.2019 |
Independent Dir/Board Member | 01.05.2015 | 19.06.2019 |
Ausbildung von Andrew J. Staples
The University of Sheffield | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Entasis Therapeutics, Inc.
![]() Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
![]() Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Andrew J. Staples
- Erfahrung